Literature DB >> 7756101

Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity.

L J Notarianni1, S E Oliver, P Dobrocky, P N Bennett, B W Silverman.   

Abstract

1. Caffeine is widely used as an in vivo probe for CYP1A2; the distribution/activity of this enzyme is reported to be reflected by metabolic ratios. 2. Several metabolic ratios using different combinations of urinary metabolites have been used to measure CYP1A2, with varying conclusions on its distribution. 3. A mathematical comparison of five metabolic ratios claiming to reflect CYP1A2 activity was made using data from 237 healthy volunteers. 4. All five metabolic ratios were symmetrically distributed. The five ratios however, measured at least three different parameters, with no one ratio correlating exactly with any other. 5. Data in the literature claiming to measure CYP1A2 using caffeine may reflect other parameters. 6. The complex metabolism of caffeine together with different parameters controlling the renal clearance of each metabolite, makes the use of urinary metabolic ratios an inaccurate probe for assessing the distribution of CYP1A2 activity in populations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7756101      PMCID: PMC1364983          DOI: 10.1111/j.1365-2125.1995.tb04411.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Genetic control of isoniazid metabolism in man.

Authors:  D A EVANS; K A MANLEY; V A McKUSICK
Journal:  Br Med J       Date:  1960-08-13

2.  Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.

Authors:  M A Butler; M Iwasaki; F P Guengerich; F F Kadlubar
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

3.  Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites.

Authors:  F F Kadlubar; G Talaska; M A Butler; C H Teitel; J P Massengill; N P Lang
Journal:  Prog Clin Biol Res       Date:  1990

4.  A urinary metabolite ratio that reflects systemic caffeine clearance.

Authors:  M E Campbell; S P Spielberg; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1987-08       Impact factor: 6.875

5.  Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities.

Authors:  W Kalow; B K Tang
Journal:  Clin Pharmacol Ther       Date:  1991-11       Impact factor: 6.875

6.  Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes.

Authors:  M E Campbell; D M Grant; T Inaba; W Kalow
Journal:  Drug Metab Dispos       Date:  1987 Mar-Apr       Impact factor: 3.922

7.  Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine.

Authors:  K Vistisen; H E Poulsen; S Loft
Journal:  Carcinogenesis       Date:  1992-09       Impact factor: 4.944

8.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

9.  Quantitative assessment of caffeine partial clearances in man.

Authors:  A Lelo; J O Miners; R A Robson; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

10.  Effect of allopurinol on caffeine disposition in man.

Authors:  D M Grant; B K Tang; M E Campbell; W Kalow
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

View more
  5 in total

1.  Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo.

Authors:  J T Larsen; L L Hansen; K Brosen
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 2.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

3.  Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population.

Authors:  D S Ou-Yang; S L Huang; W Wang; H G Xie; Z H Xu; Y Shu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

4.  Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls.

Authors:  Maria Skaalum Petersen; Jónrit Halling; Per Damkier; Flemming Nielsen; Philippe Grandjean; Pál Weihe; Kim Brøsen
Journal:  Eur J Clin Pharmacol       Date:  2006-11-07       Impact factor: 2.953

5.  NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.

Authors:  A Nyéki; T Buclin; J Biollaz; L A Decosterd
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.